Warning Flags™ is our proprietary risk-scoring model for CNS drug development programs. It evaluates candidates across target validation, ADME, safety, CMC, clinical, regulatory, IP, and financial dimensions, generating a score from 0 to 66+ mapped to a twelve-tier color scale from Green (clear investment conditions) to Black (do not commit capital). This edition runs four entactogen candidates through the model simultaneously.
The MDMA-AT failure in 2024 left a field, not a void. The FDA's rejection of the Lykos NDA, citing functional unblinding, inadequate data integrity, and unresolved risks, did not invalidate the therapeutic thesis. It raised the bar for what a fundable entactogen program needs to look like. Four candidates now compete to clear it.
We scored all four against the same parameters: PTSD indication, current development stage, publicly available data only.
MBDB: 40.8 (Purple Flag). MDEA: 43.8 (Purple Flag). Methylone (TSND-201): 4.0 (Green/Striped Flag). Hypothetical best-case NCE: 2.0 (Green Flag).
The gap between the first two and the second two is 37 points. That number tells the story of this field more clearly than any single pharmacological comparison.
MBDB and MDEA are the most pharmacologically characterized known entactogens outside of MDMA itself. Both were synthesized and self-administered by Alexander Shulgin, with detailed notes in PiHKAL. Neither has entered a clinical trial. The Purple Flag at preclinical is not a pharmacological verdict. It reflects two critical structural findings that apply to any known molecule at this stage: no public GLP toxicology package exists in the literature, and composition-of-matter patents expired decades ago. Both molecules are public domain. Any IP strategy built around them depends on method-of-use patents alone, a structurally weaker position than a true NCE. For any organization developing these compounds, the path to IND starts from a thin public data package and a weak IP foundation, and that is capital-intensive regardless of how interesting the pharmacology is.
The 3-point gap between MBDB and MDEA traces to two findings. MDEA carries a broader monoamine release profile, with meaningful dopamine and norepinephrine output alongside serotonin, plus an inferred hERG/QTc concern from that broader catecholamine activity. MBDB is essentially dopamine-silent, with an EC50 for dopamine release exceeding 100,000 nM versus 540 nM for serotonin (Nagai et al., 2007). That selectivity advantage is real, but it does not move the flag. Both compounds still carry a neurotoxicity signal: MDEA was approximately one-fourth as potent as MDMA in producing long-term serotonin depletion in rodents (Ricaurte et al., 1987), and MBDB produces reduced but not absent serotonergic neurotoxicity. Safer than MDMA. Not clean.
“On the current evidence, no program in this field has cleared those hurdles. Methylone is simply the furthest along.”
Methylone tells a different story. At Phase 2 with positive JAMA Psychiatry data, Breakthrough Therapy Designation, a National Priority Voucher, and an Otsuka acquisition behind it, the program generates 18 positive findings that overwhelm its residual concerns. The two remaining high flags, moderate patent estate and crowded competitive landscape, are inherited constraints of any known molecule in an active field, not program-specific failures. Green/Striped at Phase 2 is a strong result.
The hypothetical best-case NCE scores Green at preclinical. True NCE origin, clean composition-of-matter patent, full GLP package, high selectivity, no neurotoxic signal, experienced team. At 2.0, it edges out methylone by two points, but methylone is already in Phase 3 recruitment with a major pharma partner. The hypothetical NCE still has to survive IND, Phase 1, and Phase 2 before it can make that comparison meaningful.
That is the investment read. The known molecules without development programs behind them are not investable at current stage, not because the pharmacology fails, but because the structural gaps are too large. Methylone has already cleared those gaps and is executing. The purpose-built NCE represents the ceiling of what the field could look like, but ceiling and present value are different things.
Methylone is not a winner. It is a leader. Phase 3 can fail. DEA scheduling is not guaranteed. The blinding problem that contributed to MDMA's NDA rejection hasn't been solved for any entactogen. On the current evidence, no program in this field has cleared those hurdles. Methylone is simply the furthest along.
The question for the next five years is not which known molecule is most interesting. It is whether any organization can build a purpose-built entactogen NCE, clear the IND, generate Phase 2 data, and close the gap on a program that already has a two-year head start and a $1.2 billion acquisition behind it.
Warning Flags gives a clear answer on what that program needs to look like. It does not yet exist in the public domain.
References
- Nagai, T., Nonaka, R., Satoh, K., Hisashi, K., & Kamimura, H. (2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Forensic Science International, 173(2–3), 106–114.
- Ricaurte, G.A., Finnegan, K.F., Nichols, D.E., DeLanney, L.E., Irwin, I., & Langston, J.W. (1987). 3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. European Journal of Pharmacology, 137, 265–268.
- Shulgin, A., & Shulgin, A. (1991). PiHKAL: A Chemical Love Story. Transform Press.